Nearly half a million women in the United States are affected by breast and ovarian cancer each year. Unfortunately, many will be diagnosed with aggressive forms of these cancers. Women with high-grade serous ovarian cancer or triple-negative breast cancer face a much higher mortality rate. Triple-negative breast cancer is more likely to strike minority women and those under age 50.
These two advanced cancers share similar genetic causes, giving us a unique opportunity to make significant progress in treatment and prevention of both diseases.
MD Anderson’s Breast/Ovarian Cancer Moon Shot is a coordinated effort to attack two deadly cancers at the same time by combining the latest treatment technology and genetic knowledge to identify the most promising new treatments and move them into a clinical setting in a faster, more efficient way.